Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 85.8% in October

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 50,900 shares, an increase of 85.8% from the October 15th total of 27,400 shares. Based on an average daily volume of 44,500 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.7% of the shares of the company are short sold.

Avenue Therapeutics Stock Up 2.7 %

ATXI traded up $0.05 during trading on Friday, hitting $1.93. 106,413 shares of the company traded hands, compared to its average volume of 60,642. Avenue Therapeutics has a one year low of $1.60 and a one year high of $26.47. The stock’s fifty day moving average is $2.32 and its 200 day moving average is $3.00. The firm has a market cap of $2.76 million, a P/E ratio of 0.06 and a beta of -0.17.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned 7.97% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is currently owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.